A Multi-Institutional Phase II Study of the Efficacy and Tolerability of Lapatinib in Patients with Advanced Hepatocellular Carcinomas
Authors:
- Tanios Bekaii-SaabTBTanios Bekaii-Saab
- Joseph MarkowitzJMJoseph Markowitz
- Nichole PrescottNPNichole Prescott
- Wolfgang SadeeWSWolfgang Sadee
- Nyla HeeremaNHNyla Heerema
- Lai WeiLWLai Wei
- Zunyan DaiZDZunyan Dai
- Audrey PappAPAudrey Papp
- Angela CampbellACAngela Campbell
- Kristy CullerKCKristy Culler
- Catherine BalintCBCatherine Balint
- Bert O'NeilBOBert O'Neil
- 14 September 2009
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 15 (18) , 5895-5901
Abstract
Background: Hepatocellular carcinoma (HCC) is on the rise worldwide. HCC responds poorly to chemotherapy. Lapatinib is an inhibitor of epidermal growth factor receptor and HER2/NEU both implicated in hepatocarcinogenesis. This trial was designed to determine the safety and efficacy of lapatinib in HCC. Methods: A Fleming phase II design with a single stage of 25 patients with a 90% power to exclude a true response rate of 120 days. Median progression-free survival was 1.9 months and median overall survival was 12.6 months. Patients who developed a rash had a borderline statistically significant longer survival. Tissue and blood specimens were available on >90% of patients. No somatic mutations in EGFR (exons 18-21) were found. In contrast to our previous findings, we did not find evidence of HER2/NEU somatic mutations. PTEN, P-AKT, and P70S6K expression did not correlate with survival. Conclusions: Lapatinib is well-tolerated but seems to benefit only a subgroup of patients for whom predictive molecular or clinical characteristics are not yet fully defined. (Clin Cancer Res 2009;15(18):5895–901)Keywords
This publication has 50 references indexed in Scilit:
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Expression of Signaling Mediators Downstream of EGF-Receptor Predict Sensitivity to Small Molecule Inhibitors Directed Against the EGF-Receptor PathwayJournal of Thoracic Oncology, 2008
- SorafenibDrugs, 2008
- Phase II Study of Sorafenib in Patients With Advanced Hepatocellular CarcinomaJournal of Clinical Oncology, 2006
- Phase II Study of Erlotinib in Patients With Advanced Biliary CancerJournal of Clinical Oncology, 2006
- Sample size tables for exact single‐stage phase II designsStatistics in Medicine, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Treatment of hepatocellular carcinomaHepatology, 1997
- Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patientsCancer, 1989
- Systemic and regional treatment of primary carcinoma of the liverCancer Treatment Reviews, 1977